Indian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...

Laurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...

Investor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

Indian equities are poised for fresh highs, driven by strong earnings and sector-specific momentum, particularly in financials and manufact...

Abakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Helios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...

Artificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI s...

ValueQuest's Sameer Shah champions a private equity approach to public markets. He focuses on deep research and conviction in identifying t...

Indian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...

Rising crude oil prices are pressuring chemical sector margins due to increased feedstock and energy costs. Despite this, the Nifty Chemica...

Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defenc...

Market expert Vikas Khemani anticipates a consolidation phase for Indian equities rather than a sharp breakout, citing persistent global ma...

Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...

Shares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its C...